Sunday, March 15, 2020 10:36:48 PM
Roche Gets Emergency Approval for First Fast Covid-19 Test -- Barrons.com
10:08 am ET March 13, 2020 (Dow Jones) Print
By Bill Alpert
The first high-speed coronavirus test was approved by the U.S. Food and Drug Administration, said Roche Holding today. The Swiss medical giant's new test works in its high-volume cobas 6800/8800 systems -- widely used diagnostic machines that will be able to process up to 4,000 of the Covid-19 tests per hour. That's 10 times faster than currently used tests.
There are more than 800 of the automated Roche systems around the world, the company has said, including about 110 in the U.S. More have been placed in recent weeks. Millions of units of the Roche test will be available for the hospital and commercial labs that use its system, the company said.
Diagnostic products like the new test account for 20% of the $62 billion in revenue reported in 2019 by the company. Roche stock (ticker: ROG.Switzerland) is up 8.5% today on the news, to 298 Swiss francs (U.S. $313).
"Over the last weeks, our emergency response teams have been working hard to bring this test to the patients," said the chief of Roche Diagnostics, Thomas Schinecker, in the company's announcement.
Approved under the FDA's "emergency use authorization," the Roche test is only the third test licensed in the U.S., coming after two slower diagnostics developed by the Centers for Disease Control and Prevention and by New York state.
Frustrated with the response speed of the U.S. federal government, states like New York have made their own arrangements with medical labs to handle testing for Covid-19. South Korea was hit early by the outbreak and has now performed more than 20 times as many tests than the U.S., despite having only 16% as many citizens.
Write to Bill Alpert at william.alpert@barrons.com
(END) Dow Jones Newswires
10:08 am ET March 13, 2020 (Dow Jones) Print
By Bill Alpert
The first high-speed coronavirus test was approved by the U.S. Food and Drug Administration, said Roche Holding today. The Swiss medical giant's new test works in its high-volume cobas 6800/8800 systems -- widely used diagnostic machines that will be able to process up to 4,000 of the Covid-19 tests per hour. That's 10 times faster than currently used tests.
There are more than 800 of the automated Roche systems around the world, the company has said, including about 110 in the U.S. More have been placed in recent weeks. Millions of units of the Roche test will be available for the hospital and commercial labs that use its system, the company said.
Diagnostic products like the new test account for 20% of the $62 billion in revenue reported in 2019 by the company. Roche stock (ticker: ROG.Switzerland) is up 8.5% today on the news, to 298 Swiss francs (U.S. $313).
"Over the last weeks, our emergency response teams have been working hard to bring this test to the patients," said the chief of Roche Diagnostics, Thomas Schinecker, in the company's announcement.
Approved under the FDA's "emergency use authorization," the Roche test is only the third test licensed in the U.S., coming after two slower diagnostics developed by the Centers for Disease Control and Prevention and by New York state.
Frustrated with the response speed of the U.S. federal government, states like New York have made their own arrangements with medical labs to handle testing for Covid-19. South Korea was hit early by the outbreak and has now performed more than 20 times as many tests than the U.S., despite having only 16% as many citizens.
Write to Bill Alpert at william.alpert@barrons.com
(END) Dow Jones Newswires
New York Yankees and Duke Basketball
Recent RHHBY News
- Genentech Highlights New Breast Cancer and Precision Oncology Data Ahead of ASCO 2026 (RHHBY) • IH Market News • 05/19/2026 02:48:10 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • InvestorsHub NewsWire • 04/22/2026 01:00:00 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) • GlobeNewswire Inc. • 04/09/2026 10:59:00 AM
- /C O R R E C T I O N -- Roche/ • PR Newswire (US) • 03/24/2026 08:05:00 PM
- /C O R R E C T I O N -- Roche/ • PR Newswire (US) • 03/24/2026 07:27:00 PM
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets • PR Newswire (US) • 03/24/2026 06:00:00 AM
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets • PR Newswire (US) • 03/24/2026 06:00:00 AM
- Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation • PR Newswire (US) • 03/18/2026 01:00:00 PM
- Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease • PR Newswire (US) • 03/16/2026 06:00:00 AM
- Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease • PR Newswire (US) • 03/16/2026 06:00:00 AM
- New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools • PR Newswire (US) • 03/05/2026 06:15:00 AM
- Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development • InvestorsHub NewsWire • 02/19/2026 02:00:00 PM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 01/28/2026 07:33:05 PM
- Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation • AllPennyStocks.com • 01/05/2026 05:38:00 PM
- When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology • AllPennyStocks.com • 12/22/2025 11:45:00 AM
- AstraZeneca Reports Fasenra Misses Primary Endpoint in COPD Study • UK Market News • 09/17/2025 08:28:22 AM
- Stopping Cancer Before It Spreads: The EMT Revolution in Oncology • AllPennyStocks.com • 09/08/2025 12:00:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • InvestorsHub NewsWire • 07/07/2025 01:00:00 PM
